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Background: The polyomaviruses WUPyV and KIPyV have been detected in various sample types including feces
indicating pathogenicity in the gastrointestinal (GI) system. However, quantitative viral load data from other
simultaneously collected sample types are missing. As a consequence, primary replication in the GI system cannot
be differentiated from swallowed virus from the respiratory tract.
Here we present a retrospective quantitative longitudinal analysis in simultaneously harvested specimens from
different organ sites of patients undergoing hematopoietic stem cell transplantation (HSCT). This allows the
definition of sample types where deoxyribonucleic acid (DNA) detection can be expected and, as a consequence,
the identification of their primary replication site.
Findings: Viral DNA loads from 37 patients undergoing HSCT were quantified in respiratory tract secretions (RTS),
stool and urine samples as well as in leukocytes (n = 449). Leukocyte-associated virus could not be found. WUPyV
was found in feces, RTS and urine samples of an infant, while KIPyV was repeatedly detected in RTS and stool
samples of 4 adult patients.
RTS and stool samples were matched to determine the viral load difference showing a mean difference of 2.3 log
copies/ml (p < 0.001).
Conclusions: The data collected in this study suggest that virus detection in the GI tract results from swallowed
virus from the respiratory tract (RT). We conclude that shedding from the RT should be ruled out before viral DNA
detection in the feces can be correlated to GI symptoms.
Keywords: WU polyomavirus, KI polyomavirus, Gastrointestinal Tract, Respiratory system, Urine, Hematopoietic Stem
Cell Transplantation, Immunocompromised Host, Viral LoadFindings
Background
In 1971, the first human pathogenic polyomaviruses
(PyV) BKV and JCV were discovered in severely im-
munosuppressed patients [1,2]. Since then, BKV and
JCV have been detected in various sample types from
different organ systems including urine specimens,
serum samples and leukocytes, which seem to form the
vehicle for virus spread [3-6].* Correspondence: motamedi@mvp.uni-muenchen.de
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distribution, and reproduction in any mediumThe two polyomaviruses WU polyomavirus (WUPyV)
and KI polyomavirus (KIPyV) were first described in 2007
[7,8]. Recent findings imply that primary contact occurs
during childhood resulting in a persistent infection [9-11].
They have mainly been detected in respiratory tract (RT)
secretions (RTS) but also in stool samples [7,12-17], rais-
ing the question of a causal connection to gastrointestinal
(GI) symptoms [13-16,18]. So far, however, no clear asso-
ciation between virus detection and specific symptoms
could be shown. Like previously described for BKV/JCV,
an association between the appearance of WUPyV/KIPyV
and immunosuppression – especially with hematopoietictral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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observed [9,13,14,19]. In analogy to findings of BKV and
JCV in leukocytes [3-6], a hematologic reservoir is also
suspected for WUPyV and KIPyV [16].
To elucidate the tissue tropism of these viruses many
studies followed a cross-sectional design. Such studies,
however, have not revealed significantly different preva-
lence rates for patients and control groups [20,21].
Hence, as seen for BKV/JCV, quantitative assignment of
viral loads could be indicative for clinically relevant viral
replication [22]. This theory is supported by a recent
study reporting higher KIPyV loads in RTS of patients
undergoing HSCT than of the control group [20].
As mentioned, WUPyV/KIPyV DNA has been
detected in stool samples. However, a common challenge
when detecting viral DNA in the GI tract is the differen-
tiation between possibly pathogenic primary replication
and secondary shedding due to swallowed virus [23].
This problem can only be addressed by longitudinal viral
DNA quantification in different simultaneously collected
sample types.
Therefore, we performed this retrospective analysis to
provide quantitative viral load data in different speci-
mens of patients undergoing HSCT. Furthermore, we
address the question of genuine viral replication in the
gastrointestinal tract as opposed to detection of viral
DNA by polymerase chain reaction (PCR) due to sec-
ondary shedding from the respiratory system.
Material and methods
A retrospective analysis for the prevalence of WUPyV
and KIPyV in HSCT-patients was performed with a total
of 449 clinical samples from 37 HSCT-patients. These
patients were routinely screened for viral pathogens
throughout HSCT-therapy, which comprised WUPyV
and KIPyV as well as EBV, CMV, HHV6 and Adenovirus.
In case of a clinical suspicion, further PCR testing was
performed for HSV, Norovirus, Rotavirus, Parvovirus
B19, Influenza virus and Parainfluenza virus.
The study was conducted in accordance with the Dec-
laration of Helsinki. All patients gave informed consent
to virological surveillance, collection and publication of
data. Approval was waived by the ethics committee of
the Ludwig-Maximilians-University.
Assays were carried out according to standard detec-
tion techniques of the accredited laboratory for viro-
logical diagnostics of the Max von Pettenkofer-Institute.
The study comprised RTS (throat washes, bronchoale-
veolar lavages, endotracheal suctions), stool and urine
samples and leukocytes. Samples were stored at 4°C and
nucleic acid was extracted within 24 h with the High Pure
Viral Nucleic Acid Kit (Roche Applied Biosystems). Leu-
kocytes were adjusted to a cell number of 20,000 cells/






GmbH, Martinsried, Germany). Positive control plasmids
for WUPyV and KIPyV were kindly provided by Benedikt
Weißbrich (University of Würzburg, Germany).
The sensitivity threshold of the assay with a detection
probability of 90% was 7 copies/20,000 cells for leuko-
cytes and was 350 copies/ml for RTS, stool and urine
samples, corresponding to 2.54 log copies/ml.
RTS and stool samples that tested positive were
matched to define the mean difference between viral
loads in RTS and stool samples.
Our statistical inference regarding the differences in
log viral loads was based on a two-sided paired t test. A
p value < 0.05 was regarded as significant.Results
Initial analysis
During the initial analysis, 19 out of 208 specimens
taken from 37 patients tested positive for WUPyV or
KIPyV. Positive results could be assigned to 5 patients
(total number of samples from these 5 patients: 64)
(Table 1). KIPyV was detectable in RTS and stool sam-
ples from 4 adult patients, whereas WUPyV was found
in RTS, stool and urine samples of an infant.Follow-Up
In these 5 patients, viral loads were defined over time in
another 241 samples from different organ sites (RTS,
stool, leukocytes, urine; total: 305 samples) (Figures 1, 2).
All patients had a period of diarrhea during HSCT
which coincided with detection of WUPyV/KIPyV, but
also with mucositis and Graft versus Host Disease
(GvHD – stages were defined according to Glucksberg
et al. [25]) of the gut and detection of co-infecting
pathogenic viruses (Table 1). Thus, primary and possibly
pathogenic replication in the gastrointestinal tract
needed to be differentiated from secondary shedding
events from the RT. For this purpose, RTS and stool
specimens collected with a maximum time difference of
24 hours were matched in pairs (n = 34) and viral load
differences were defined. A significant mean viral load
difference of 2.3 log copies/ml was determined between
these 2 sample types (p < 0.001).
Repeated testing of leukocytes showed neither KIPyV
nor WUPyV. Leukocyte-associated viremia was therefore
not seen in these patients despite simultaneous detection
of high viral titers in other specimens and the severe im-
munosuppression throughout HSCT-therapy.
Table 1 Characteristics of the 5 hematopoietic stem cell transplantation (HSCT) patients presenting WUPyV or KIPyV










Chronic (skin, gut - max. IV°) Cidofovir (days +121 to +272) HHV6, HSV HHV6 HHV6 (leukocytes), BKV,
HHV6 (urine)
2 Allogeneic PBSCT Chronic ( skin, gut - max. IV°) Cidofovir, Ribavirin
( days +118 to +176)
EBV, HHV6, HSV Adenovirus, EBV EBV, HHV6, Adenovirus
(leukocytes)
3 Allogeneic BMT Acute (skin - max. II°) Foscarnet ( days +19 to +55),
Cidofovir ( days +55 to +138)
HHV6, EBV none EBV (leukocytes)
4 Allogeneic PBSCT Acute (gut - max. III°) none HHV6 HHV6 HHV6, EBV (leukocytes)
WUPyV
(infant)
5 Allogeneic PBSCT Chronic (pre-PBSCT: skin, gut,
hematopoietic system - max. III°)
Cidofovir ( days +17 to +58) HHV6, Adenovirus,
HHV7, HSV
Norovirus, Adenovirus, HHV6 HHV6 (urine)
Clinical data summary for the HSCT patients that tested positive for WUPyV and KIPyV including detected co-infecting viruses throughout the observation period and antiviral therapy; Antiviral therapy: all patients
received prophylactic Acyclovir therapy. Further antiviral therapy is depicted with time-points (day 0: day of HSCT). Co-infecting viruses in RTS, stool and further samples in order of detection frequency. GvHD: Graft















Figure 1 Courses of KIPyV load in respiratory tract samples and stool samples in 4 adult patients. Quantitative Real Time-PCR was
performed to determine viral loads (copies/ml) in different specimens before and after hematopoietic stem cell transplantation (HSCT). The 90%
sensitivity threshold was at 350 copies/ml corresponding to 2.54 log copies/ml indicated by the horizontal dotted line. The bold line represents
day 0 of HSCT; the dashed vertical line shows time point of neutrophil granulocyte engraftment. Please note that most samples were collected
after HSCT. RTS: respiratory tract secretion.
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Figure 2 Courses of WUPyV viral load in respiratory tract
samples, stool and urine samples in infant patient 5.
Quantitative Real Time-PCR was performed to determine viral loads
(copies/ml) in different specimens before and after hematopoietic
stem cell transplantation (HSCT). The 90% sensitivity threshold was
at 350 copies/ml corresponding to 2.54 log copies/ml indicated by
the horizontal dotted line. The bold line represents day 0 of HSCT;
the dashed vertical line shows time point of neutrophil granulocyte
engraftment. RTS: respiratory tract secretion.
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RTS as well as in urine samples (Figure 2). Previous
studies indicate that primary infection with WUPyV/
KIPyV occurs during childhood [9-11]. Thus, this could
have been a case of primary infection for WUPyV which
led to virus detection in the urine with lower viral loads
than in RTS and stool samples.
KIPyV was not detectable in urine samples at any time
point.
Prophylactic therapy with Acyclovir was routinely per-
formed for all patients under HSCT. Further antiviral
therapy is depicted in Table 1. All patients presented
HHV6, among other co-infecting viruses (Table 1).Patients 1 and 2 had chronic Graft versus Host Disease
(maximum WHO stage 4) until the end of the observa-
tion period that was treated with high doses of various
immunosuppressants including Infliximab. Patient 1
developed a BKV-associated hemorrhagic cystitis. For
this reason and for the HHV6-infection (Table 1), anti-
viral therapy with Cidofovir was initiated on day +121
and lasted till the end of observation. While he could
not clear BKV throughout the course of analysis, he did
clear KIPyV (Figure 1).
Patient 2 was treated with Cidofovir and Ribavirin
from day +118 to +176. From day +71 to +99 he had
received 5 doses of Infliximab. The first time-point of
virus detection was at day +82, followed by a steady de-
cline and clearing of KIPyV until day + 246 (Figure 1).
Patient 3 was treated with Foscarnet and Cidofovir for
HHV6 and EBV (Table 1) from day +55 to +138. Clear-
ing of virus coincided with antiviral treatment and neu-
trophil engraftment.
Patient 4 did not receive further antiviral therapy and
cleared the virus after a viral load peak of 6.1 log copies/
ml 21 days after neutrophil engraftment.
Patient 5 presented WUPyV among various co-
infecting viruses. For an adenoviral infection, he was
treated with Cidofovir from day +17 to +58, which coin-
cides with clearing of the virus from the urine, but not
in RTS or stool samples.
Conclusions
In this retrospective longitudinal study, a total of 449
samples (RTS, stool, urine, leukocytes) from 37 HSCT-
patients were quantitatively analyzed for the polyoma-
viruses WUPyV and KIPyV. KIPyV was found in RTS
and stool samples of four adult patients, while an infant
presented WUPyV in RTS and stool samples as well as
in urine.
Recent studies raised the question of a causal connec-
tion between WUPyV/KIPyV detection in the stool and
the appearance of GI symptoms [13-16,18]. In this study,
viral loads in RTS and stool samples correlated consist-
ently. A mean viral load difference of 2.3 log copies/ml
(p < 0.001) between respiratory and stool samples was
observed. This suggests the RT as the primary site of rep-
lication with virus detection in feces resulting from swal-
lowed virus. We conclude that, when screening for
WUPyV or KIPyV in stool samples to define associated
symptoms, respiratory secretions should be simultan-
eously analyzed to rule out viral shedding from the re-
spiratory tract.
These polyomaviruses were repeatedly detected in all 5
patients and viral load courses could be quantified.
Clearing of KIPyV coincided with Cidofovir therapy in
patients with severe immunosuppressive therapy due to
high-grade GvHD and with immune reconstitution as
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patients with moderate immunosuppressive therapy, re-
spectively. Cidofovir is a treatment option for BKV [4],
and might therefore have antiviral activity on related
viruses, such as WUPyV or KIPyV. Therefore, more
studies are needed to exclude or to specify a possible im-
pact of this substance and to further define factors asso-
ciated with viral replication taking into account clinical
symptoms as well as medication and immune status.
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